Kowa

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Retrieved on: 
월요일, 4월 22, 2024
Poster, Marshal of France, International, Drug, Bausch & Lomb, Research, Depreciation, Mass meeting, Sale, NCX, IOP, Kowa, ARVO, Patent, Patient, COVID-19, Nitric oxide, Ocular hypertension, Glaucoma, BlackRock, Pharmaceutical industry

“Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.

Key Points: 
  • “Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.
  • The Nicox Board of Directors has co-opted Dr Gavin Spencer, CEO of Nicox, as a Board member with effect from April 8, 2024.
  • The debt restructuring amendment which was agreed in principle between Nicox and BlackRock and announced on February 28, 2024 was signed.
  • The audit procedures on the 2023 statutory financial statements of Nicox SA have been completed and the certification report is in the process of being issued.

Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO

Retrieved on: 
수요일, 2월 28, 2024
Pfizer, Chemistry, Bausch & Lomb, Novartis, Doctor of Philosophy, University, Therapy, Boots (company), NCX, Corporation, Glaucoma, Kowa, Partnership, Management

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.

Key Points: 
  • Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.
  • “I am delighted to welcome Gavin Spencer to his new role as CEO of Nicox.
  • Gavin brings exhaustive industry experience, particularly related to strategic partnership agreements and financing.
  • During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.

Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan

Retrieved on: 
목요일, 2월 8, 2024
IOP, Intraocular pressure, Glaucoma, Kowa, Therapy, Ophthalmology, Patient, Marketing, NCX, Business development, Ocular hypertension, Business, Pharmaceutical industry

“We are very pleased to welcome Kowa as an exclusive partner for our lead asset, NCX 470, for the Japanese market.

Key Points: 
  • “We are very pleased to welcome Kowa as an exclusive partner for our lead asset, NCX 470, for the Japanese market.
  • Kowa shall be responsible for all development, regulatory and commercialization costs for NCX 470 in Japan.
  • Kowa expects to conduct additional clinical trials in Japanese patients as required for regulatory approval of NCX 470 in Japan in addition to the development data from Nicox.
  • Including the upfront payment from the Japanese licensing deal for NCX 470, the Company estimates it is currently funded until September 2024, exclusively based on the development of NCX 470.

Adani Power to Co-fire Green Ammonia at its Mundra Plant for a Sustainable Future

Retrieved on: 
수요일, 11월 29, 2023
Research, Environment, Climate Change, Utilities, Chemicals, Plastics, Sustainability, Alternative Energy, Manufacturing, Energy, Science, NEDO, Carbon, New energy, CO2, APL, Electrolysis, IHI, Adani Power, Renewable energy, Conference, Ammonia, CEP, COP, Coal, Kowa

As part of the project, the Mundra Plant, which is India’s largest private sector power plant, will co-fire up to 20% green ammonia in the boiler of a conventional coal fired 330MW Unit.

Key Points: 
  • As part of the project, the Mundra Plant, which is India’s largest private sector power plant, will co-fire up to 20% green ammonia in the boiler of a conventional coal fired 330MW Unit.
  • Green ammonia, produced from green hydrogen, which in turn is produced through electrolysis using renewable energy, would be a feedstock for the boilers.
  • Combustion tests at IHI’s facility in Japan have begun with 20% ammonia blend, simulating Mundra Power Station equipment.
  • The Mundra plant is the first location outside of Japan to have been selected for this cutting-edge green initiative.

Envoy Technologies launches first electric car share in Hawaii

Retrieved on: 
목요일, 2월 24, 2022
Nissan Leaf, Partnership, Movement, Travel, Multimedia, Technology, Kowa, Online shopping, Envoy

HONOLULU, Feb. 24, 2022 /PRNewswire/ -- Envoy Technologies announced the launch of its first electric car share in Hawaii in partnership with Kowa American powered by the Envoy Mobility app.

Key Points: 
  • HONOLULU, Feb. 24, 2022 /PRNewswire/ -- Envoy Technologies announced the launch of its first electric car share in Hawaii in partnership with Kowa American powered by the Envoy Mobility app.
  • Envoy's Mobility as an Amenity service and technology platform provides residents with freedom of movement without the expense of traditional car ownership or hassle of renting a car.
  • Electric car share provides Honolulu residents with freedom of movement without expense of traditional car ownership.
  • See photos of Envoy's new location in Hawaii: https://www.envoythere.com/post/envoy-launches-first-electric-car-share-...
    Envoy Technologies, is a technology and mobility service company offering shared electric vehicles where people live, work and stay.